AI assistant
BOIRON Earnings Release 2022
1161_10-q_2022-04-22_e20c5a82-871c-4160-8d92-57af2071eeef.pdf
Earnings Release
Open in viewerOpens in your device viewer
BOTRON®
April 21, 2022
2022 FIRST QUARTER BOIRON SALES
(Unaudited data)
| Variation at | Variation at | |||
|---|---|---|---|---|
| In thousands of euros | 2022 | 2021 | current | constant |
| exchange rates | exchange rates | |||
| France | 77,055 | 51,518 | +49.6% | +49.6% |
| Europe (excluding France) | 34,476 | 20,039 | +72.0% | +74.2% |
| North America | 28,944 | 17,657 | +63.9% | +52.6% |
| Other countries | 5,305 | 1,958 | +171.0% | +160.0% |
| Group total | 145,780 | 91,172 | +59.9% | +58.0% |
| Variation at | Variation at | |||
| In thousands of euros | 2022 | 2021 | current | constant |
| exchange rates | exchange rates | |||
| Non-proprietary Homeopathic Medicines | 45,516 | 46,352 | -1.8% | -2.8% |
| Homeopathic Specialties | 67,100 | 39,430 | +70.2% | +67.0% |
| Other health products* | 33,164 | 5,390 | +515.3% | +514.6% |
| Groun total | 145-780 | 91.172 | +59.9% | +58.0% |
* "Other healthcare products" include the non-homeopathic products (medical devices, nutritional supplements, cosmetics, phytotherapy) that were previously listed in the "OTC specialty" section.
Changes in turnover
During the 1st quarter of 2022, turnover increased sharply across all geographic regions due to:
- the base effect created by the steep drop in turnover during the 15 quarter of 2021 (-41.8%) due to the pandemic,
- growth in homeopathic specialty medicines,
- growth in other healthcare products, particularly COVID tests, which were not yet on the market in France during the 1st quarter of 2021,
- our continued strategy of innovation, particularly with the launch of Varésol®, a new homeopathic medicine indicated for chickenpox symptoms, during the first quarter of this year.
Outlook
The Group's sales may be affected by the current geopolitical situation. We are closely monitoring the situation and its impact as they develop and are taking all the necessary measures for the organization of our activities.
However, we do anticipate increased turnover in 2022 and we continue to put all our energy and determination into the promotion of homeopathy in France and around the world.
Laboratoires BOIRON
Our next updates:
The Ordinary Shareholders' Meeting will be held on Meddyorters, 2 avenue de l'Ouest Lyonnois, 6950 MESSMY - FRANCE June 3, 2022: after approval by the Ordinary Shareholders' Meeting, payment of the proposed dividend (€0.95 per share).
- July 21, 2022: after the close of the stock market, publication of the sales on June 30, 2022.
- Person responsible for financial information: Valérie Lorentz-Poinsot
lnvestor relations: +33 (0) 4.37.41.84.01 - e-mail: [email protected]
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at : www.boironfinance.com
Contact for financial information: Fabrice Rey